Department of Nephrology, Section of Preventive Medicine, Albert-Ludwigs-University, Freiburg, D-79106 Freiburg, Germany.
J Clin Endocrinol Metab. 2010 Jan;95(1):308-13. doi: 10.1210/jc.2009-1728. Epub 2009 Nov 11.
Cancer genetics is fundamental for preventive medicine, in particular in pheochromocytoma-associated syndromes. Variants in two susceptibility genes, SDHC and RET, were found in a kindred with head and neck paraganglioma. This observation of coincident DNA variants, both reported as pathogenic, in two known susceptibility genes prompted the question of their pathogenic relevance.
Our objective was to elucidate the pathogenic role of the detected variants and study the prevalence of such variants.
Patients were registrants from the European-American Pheochromocytoma-Paraganglioma and German von Hippel-Lindau Disease Registries.
Analysis of germline mutation screening results for all pheochromocytoma-paraganglioma susceptibility genes, including RET [multiple endocrine neoplasia type 2 (MEN 2)] and VHL [von Hippel-Lindau disease (VHL)]. Cases in which more than one DNA variant was found were clinically reevaluated, and cosegregation of the disease with the variant was analyzed within the registrants' families. A total of 1000 controls were screened for the presence of detected variants, and in silico analyses were performed.
Three variants were identified, RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser. The frequencies of RET p.Ser649Leu (0.07%) and p.Tyr791Phe (0.9%) compared with controls excluded the two variants' role in the etiology of MEN 2 and VHL. None of the carriers of the RET variants who underwent prophylactic thyroidectomy showed medullary thyroid carcinoma. Clinical reinvestigation of 18 variant carriers excluded MEN 2. VHL variant p.Pro81Ser, also previously described as a mutation, did not segregate with the VHL in one family. In silico analyses for these variants predicted unmodified protein function.
RET p.Tyr791Phe and p.Ser649Leu and VHL p.Pro81Ser are definitely not pathogenic mutations for VHL and MEN 2. Misinterpretation results in irreversible clinical consequences.
癌症遗传学对于预防医学至关重要,尤其是在嗜铬细胞瘤相关综合征中。在一个家族中发现了两个易感性基因 SDHC 和 RET 的变体,该家族患有头颈部副神经节瘤。在两个已知的易感性基因中同时发现了吻合的 DNA 变体,这两种变体均被报道为致病性的,这促使人们提出了它们的致病性相关性问题。
我们的目的是阐明所检测到的变体的致病作用,并研究此类变体的流行率。
患者是来自欧洲裔美国人嗜铬细胞瘤-副神经节瘤和德国 von Hippel-Lindau 病登记处的登记患者。
对所有嗜铬细胞瘤-副神经节瘤易感性基因(包括 RET [多发性内分泌肿瘤 2 型(MEN 2)]和 VHL [von Hippel-Lindau 病(VHL)])的种系突变筛查结果进行分析。对于发现了多个 DNA 变体的病例,进行了临床重新评估,并在登记患者的家族中分析了疾病与变体的共分离。对 1000 名对照者进行了所检测到的变体存在情况的筛查,并进行了计算机分析。
确定了三个变体,RET p.Tyr791Phe 和 p.Ser649Leu 以及 VHL p.Pro81Ser。与对照组相比,RET p.Ser649Leu(0.07%)和 p.Tyr791Phe(0.9%)的频率排除了这两个变体在 MEN 2 和 VHL 病因学中的作用。接受预防性甲状腺切除术的 RET 变体携带者中均未发现甲状腺髓样癌。对 18 名变体携带者的临床再调查排除了 MEN 2。以前也被描述为突变的 VHL 变体 p.Pro81Ser 与一个家族中的 VHL 不共分离。这些变体的计算机分析预测了未修饰的蛋白功能。
RET p.Tyr791Phe 和 p.Ser649Leu 以及 VHL p.Pro81Ser 肯定不是 VHL 和 MEN 2 的致病性突变。错误解释会导致不可逆转的临床后果。